Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
ABCC1 4363 TENIPOSIDE CHEMBL452231 NCI 9865734
ABCC1 4363 MONTELUKAST CHEMBL787 PharmGKB
ABCC1 4363 ETOPOSIDE CHEMBL44657 NCI 7671247, 9472114
ABCC1 4363 ALVOCIDIB CHEMBL428690 NCI 10496352
ABCC1 4363 BENZBROMARONE CHEMBL388590 stimulator TTD
ABCC1 4363 LAMIVUDINE CHEMBL141 NCI 12218384
ABCC1 4363 SULFINPYRAZONE CHEMBL832 inhibitor, modulator TdgClinicalTrial, TEND, DrugBank, TTD 9685354, 10917554, 15044619, 11752352, 10727523, 9885294
ABCC1 4363 IRINOTECAN CHEMBL481 NCI 9918583
ABCC1 4363 BIRICODAR CHEMBL350775 modulator TTD
ABCC1 4363 THYMIDINE CHEMBL52609 NCI 9379682
ABCC1 4363 DROLOXIFENE CHEMBL487 NCI 11721384
ABCC1 4363 EPIGALOCATECHIN GALLATE CHEMBL297453 NCI 14511674
ABCC1 4363 NOVOBIOCIN CHEMBL36506 NCI 10901300
ABCC1 4363 VALSPODAR CHEMBL1086218 NCI 11189941, 9816180
ABCC1 4363 SAQUINAVIR MESYLATE CHEMBL282042 NCI 12384350
ABCC1 4363 CISPLATIN (CHEMBL2068237) CHEMBL2068237 NCI 11372415
ABCC1 4363 DIPYRIDAMOLE CHEMBL932 NCI 9664131
ABCC1 4363 DAUNORUBICIN CHEMBL178 NCI 10655559
ABCC1 4363 ERYTHROMYCIN CHEMBL532 NCI 10817732
ABCC1 4363 OFLOXACIN CHEMBL4 NCI 10817732
ABCC1 4363 PILOCARPINE CHEMBL550 NCI 15860570
ABCC1 4363 PIRARUBICIN CHEMBL1398373 NCI 12897808
ABCC1 4363 TROXACITABINE CHEMBL359164 NCI 12451476
ABCC1 4363 BUTHIONINE SULFOXIMINE CHEMBL1609891 NCI 11189941
ABCC1 4363 RITONAVIR CHEMBL163 NCI 11745741
ABCC1 4363 AZITHROMYCIN CHEMBL529 NCI 12697643
ABCC1 4363 CYCLOSPORINE CHEMBL160 NCI 11189941
ABCC1 4363 MELPHALAN CHEMBL852 NCI 14733945
ABCC1 4363 PROBENECID CHEMBL897 NCI 9182837
ABCC1 4363 SODIUM BUTYRATE CHEMBL62381 NCI 11587480

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
ABCC1 rs35592 C methotrexate metabolism/PK no Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T. 29791011 1450045031
ABCC1 rs35592 TT methotrexate efficacy yes Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT. 18256692 747980551
ABCC1 rs2238476 GG methotrexate efficacy yes Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to allele A. 18256692 747943548
ABCC1 rs28364006 GG methotrexate efficacy yes Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG. 18256692 747926545
ABCC1 rs35592 C methotrexate efficacy no Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T. 29743634 1449557891
ABCC1 rs215095 AG + GG SN-38 metabolism/PK no AUC of SN-38 was adjusted for irinotecan dose. Genotypes AG + GG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA. 27845419 1448435370
ABCC1 rs35621 CT + TT SN-38 metabolism/PK yes AUC of SN-38 was adjusted for irinotecan dose. Genotypes CT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC. 27845419 1448432559
ABCC1 rs3743527 T lamivudine efficacy no The T allele is not associated with an increased risk for virological failure (detectable viral load despite 48 weeks of highly active antiretroviral therapy (HAART) treatment) compared to the C allele. Allele T is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele C. 23996099 1183680822
ABCC1 rs212091 CC + CT lamivudine efficacy yes Patients with the CC or CT genotype had an increased risk of virological failure virological failure (detectable viral load despite 48 weeks of highly active antiretroviral therapy (HAART) treatment), as compared to those with the TT genotype. Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT. 23996099 1183680813
ABCC1 rs246240 AG + GG methotrexate efficacy yes ABCC1 rs246240 G carrier is associated with increased risk of non-response to methotrexate. Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. 26086825 1444843357
ABCC1 rs3784864 AG + GG methotrexate efficacy yes ABCC1 rs3784864 G carrier is associated with increased risk of non-response to methotrexate. Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. 26086825 1444843366
ABCC1 rs4148350 GG cyclophosphamide "efficacy","toxicity","metabolism/PK" no Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype GT. 26222310 1447676170
ABCC1 rs246221 CC cyclophosphamide "efficacy","toxicity","metabolism/PK" no Genotype CC is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype CT. 26222310 1447676158
ABCC1 rs6498588 AT + TT SN-38 metabolism/PK yes AUC of SN-38 was adjusted for irinotecan dose. Genotypes AT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA. 27845419 1448432548
ABCC1 rs8187843 AA + AG SN-38 metabolism/PK no AUC of SN-38 was adjusted for irinotecan dose. Genotypes AA + AG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype GG. 27845419 1448432589
ABCC1 rs3743527 CT + TT SN-38 metabolism/PK no AUC of SN-38 was adjusted for irinotecan dose. Genotypes CT + TT are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC. 27845419 1448435351
ABCC1 rs212082 AG + GG SN-38 metabolism/PK no AUC of SN-38 was adjusted for irinotecan dose. Genotypes AG + GG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA. 27845419 1448435381
ABCC1 rs246240 G methotrexate metabolism/PK no Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A. 29791011 1450045037
ABCC1 rs3784862 G methotrexate metabolism/PK no Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A. 29791011 1450045049
ABCC1 rs11075291 G methotrexate metabolism/PK no Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A. 29791011 1450045043